Pacira BioSciences (PCRX) to Release Quarterly Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX) is anticipated to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Pacira BioSciences to announce earnings of $0.64 per share and revenue of $191.0550 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Thursday, April 30th. The company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The firm had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. During the same quarter in the previous year, the firm earned $0.65 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $26.47 on Tuesday. The firm has a 50 day simple moving average of $24.17 and a 200-day simple moving average of $23.19. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $27.64. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of 220.60 and a beta of 0.27.

Insider Buying and Selling at Pacira BioSciences

In other news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at approximately $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Balyasny Asset Management L.P. increased its holdings in Pacira BioSciences by 36.1% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after purchasing an additional 565,288 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Pacira BioSciences by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after buying an additional 367,869 shares during the period. Marshall Wace LLP purchased a new position in shares of Pacira BioSciences in the 2nd quarter valued at about $4,550,000. First Trust Advisors LP grew its position in shares of Pacira BioSciences by 1,838.9% during the fourth quarter. First Trust Advisors LP now owns 188,889 shares of the company’s stock worth $4,888,000 after buying an additional 179,147 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Pacira BioSciences by 118.1% during the third quarter. Two Sigma Investments LP now owns 232,994 shares of the company’s stock worth $6,004,000 after buying an additional 126,152 shares in the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on PCRX. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Royal Bank Of Canada raised their target price on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research note on Friday, May 1st. Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 7th. Finally, Needham & Company LLC increased their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $29.40.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.